ProQR Therapeutics (PRQR) Invested Capital (2017 - 2026)

ProQR Therapeutics (PRQR) has reported Invested Capital for 10 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• Quarterly Invested Capital rose 6.23% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (down 2.56% YoY) and the FY2025 annual result came in at $12.6 million, down 12.21% from the prior year.
• Invested Capital fell to $5.6 million in Q1 2026 per PRQR's latest filing, from $12.6 million in the prior quarter.
• Over the last five years, Invested Capital for PRQR reached as high as $50.9 million in Q1 2022 and fell as low as $2.1 million in Q3 2022.
• A 5-year average of $9.9 million and a median of $5.4 million in 2025 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital surged 361.84% — and 2023, when it tumbled 94.25%.
• Year by year, Invested Capital stood at $17.3 million in 2022, then advanced by 1.59% to $17.6 million in 2023, then fell by 18.18% to $14.4 million in 2024, then decreased by 12.21% to $12.6 million in 2025, then tumbled by 55.42% to $5.6 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $5.6 million, $12.6 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.